Cancelation of shares of the Company owned and held by John Lauring

No definition available.

Name:	BMSN_CancelationOfSharesOfCompany
Namespace Prefix:	BMSN_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Consideration of shares of common stock of the Company

+ References

No definition available.

+ Details

Name:	BMSN_ConsiderationOfSharesOfCommonStock
Namespace Prefix:	BMSN_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- References

No definition available.

+ Details

Name:	BMSN_EquityInRegenBiopharmaInc.
Namespace Prefix:	BMSN_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Acquired share capital of Bio-Maxtrix Scientific Gruop, Inc.

+ References

No definition available.

+ Details

Name:	BMSN_ShareCapitalAcquired
Namespace Prefix:	BMSN_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- References

No definition available.

+ Details

Name:	BMSN_VotingPowerOfRegenBiopharmaInc.
Namespace Prefix:	BMSN_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 35
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848

+ Details

Name:	us-gaap_AdvertisingExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of voting equity interests acquired at the acquisition date in the business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name:	us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

+ Details

Name:	us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.3)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Related Parties
-URI http://asc.fasb.org/extlink&oid=16382449

+ Details

Name:	us-gaap_NotesReceivableRelatedParties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Apr. 01, 2016	Jul. 03, 2006
Accounting Policies [Abstract]
Acquired share capital of Bio-Maxtrix Scientific Gruop, Inc.				100.00%
Consideration of shares of common stock of the Company				10,000,000
Cancelation of shares of the Company owned and held by John Lauring				10,000,000
Percent of voting capital stock of the Company held by former stockholder of BMSG				80.00%
Equity in Regen BioPharma, Inc.	18.30%
Voting power of Regen BioPharma, Inc.	70.00%
Shares of Entest BioMedical, Inc. for Securities Available for Sale	8,066,667
Note Receivable from Entest Biomedical, Inc.			$ 52,500
Valuation allowance	100.00%
Advertising expenses	$ 0	$ 0